Reta glucagon-like peptide-1 (GLP-1) receptor agonists offer a groundbreaking strategy to diabetes management. These innovative drugs function by mimicking the physiological actions of GLP-1, a hormone secreted by the gut in response to food. By stimulating GLP-1 receptors in the pancreas, these agents boost insulin secretion and reduce glucagon se

The burgeoning landscape of novel treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a comparable therapeutic goal – improving glycemic control and promoting substantial weight loss – they exhibit intriguing contrasts in the